Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.
Akihiro MatsukawaPawel RajwaTatsushi KawadaKensuke BekkuEkaterina LaukhtinaJakob KlemmBenjamin PradereKeiichiro MoriPierre I KarakiewiczTakahiro KimuraPiotr ChlostaShahrokh F ShariatTakafumi YanagisawaPublished in: International journal of clinical oncology (2024)
Triplet therapy improves OS in mHSPC patients compared to docetaxel-based doublet therapy, irrespective of disease volume. However, based on treatment ranking, triplet therapy should preferably be considered for patients with high-volume mHSPC while those with low-volume are likely to be adequately treated with ARSI + ADT.
Keyphrases
- systematic review
- prostate cancer
- end stage renal disease
- newly diagnosed
- squamous cell carcinoma
- meta analyses
- ejection fraction
- small cell lung cancer
- chronic kidney disease
- randomized controlled trial
- stem cells
- prognostic factors
- energy transfer
- case control
- bone marrow
- mesenchymal stem cells
- cell therapy
- combination therapy
- patient reported
- free survival